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Background
Lung cancer remains the leading cause of cancer-related
deaths worldwide [1, 2]. Recent therapeutic improvements
in this disease have not substantially changed the
prognosis, with only 10–15% patients surviving 5 years
from the diagnosis. There is an urgent need for new
strategies that will impact on the global incidence of lung
cancer. Chemoprevention is an attractive concept of basic
and clinical research. Chemoprevention strategies are
expected to change the grim lung cancer statistics. The
aim of this article is to review the existing clinical data and
to present the future perspectives on lung cancer
chemoprevention. Special emphasis is given to the
controversial issue of surrogate endpoint validation and its
application in the design of chemoprevention studies.
Tobacco remains the leading cause of lung cancer
worldwide, as about 90% of cases in men and 70-80% of
cases in women are related to active smoking.
Epidemiological studies suggest a different susceptibility
of individuals to the genotoxic activity of tobacco
exposure. This is largely due to the polymorphism of
genes coding liver activation (cytochrome P450) and
detoxication enzymes (glutathione transferases) [3].
Familial occurrence of lung cancer is relatively rare;
however there is some evidence of dominant, high
penetrance oncogenes involved in the development of
lung cancer.
Currently, most new lung cancer patients are ex-
smokers, and this situation will probably continue for the
next decades [4]. It is therefore important to emphasize
the need for the development of further strategies aimed
at prevention, inhibition or reversal of the carcinogenesis
process. These strategies should optimally involve
a selected population of high-risk individuals and use
appropriate surrogate markers for efficacy evaluation [5].
Completed chemoprevention trials in lung cancer
Retrospective epidemiological studies performed over
the last two decades indicate that a diet abundant in fruit
and vegetables may decrease the incidence of lung cancer
[6]. The possible compounds considered to be linked to
decreased risk of lung cancer include retinoids – vitamin
A (retinol) derivatives, and carotenoids – conjugated
polyene molecules with antioxidant properties. Retinoids
regulate gene expression and signal transduction through
two classes of nuclear retinoid receptors – RAR and
RXR. In both classes, at least three subtypes of receptors
exist, namely α, β, and γ. These findings, together with
a number of laboratory studies that have elucidated the
possible mechanisms of the action of vitamin A
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derivatives, led to the development of chemoprevention
trials conducted in the last two decades. These trials were
designed to evaluate chemoprevention strategies on
different levels: primary (healthy high-risk individuals,
e.g. smokers), secondary (premalignant lesions) and
tertiary (second primary tumors [SPTs] in previously
treated patients).
Three randomized, large phase III clinical studies
have been conducted in a primary prevention setting: the
Alpha-Tocopherol, Beta-Carotene (ATBC) study [7], the
Beta-Carotene and Retinol Efficacy Trial (CARET, [8])
and the Physicians’ Health Study [9]. The ATBC trial
involved more than 29,000 previous and current smokers,
with a smoking history of five or more cigarettes per day.
Study subjects were randomized to beta-carotene, vitamin
E or both. In the CARET study, more than 18,000
patients with a history of asbestos exposure (over 15
years) or smoking history of at least 20 cigarette pack-
years were randomized to beta-carotene and vitamin A,
or placebo. The Physicians’ Health Study differed signifi-
cantly from the previous two trials – smokers constituted
only 11% of the study population. In this trial, about
22,000 US male physicians with no history of cancer,
myocardial infarction or stroke were randomly assigned to
beta-carotene or placebo.
In the ATBC study, an increase of 18% in the
incidence of lung cancer was found in the treatment arm,
and there was a paradoxical harmful effect of beta-
carotene/vitamin E. In the CARET study, lung cancer
occurred more frequently in the study group, yielding
a relative risk of 1.28. Interestingly, a subgroup analysis of
current versus former smokers led to strikingly different
relative risks of lung cancer incidence of 1.42 and 0.80,
respectively, compared to controls. In the Physicians’
Health Study, no effect of beta-carotene on lung cancer
incidence was found (relative risk of 0.93). The former
two studies showed that the use of high dose beta-
carotene in current smokers leads to an increased risk of
lung cancer incidence and mortality.
Another important prospective primary chemo-
prevention study included former crocidolite (blue
asbestos) workers from Western Australia. The subjects
who expressed their interest in the program were ran-
domly allocated to 30 mg of beta-carotene or 25.000 IU of
retinol daily. The first report from this study compared
overall and disease-specific mortalities in both inter-
vention groups combined vs the outcome in subjects who
did not participate in the trial [10]. Interestingly, the
adjusted relative risk of death from all causes was 0.64 in
the intervention groups (95% CI: 0.47-0.88), indicating
overall protective effect. The adjusted relative risks
of developing lung cancer and mesothelioma were 
non-significant (0.67; 95% CI: 0.33-1.37 and 0.77; 95%
CI: 0.38-1.55, respectively), and both risks differences
decreased with the duration of retinoid exposure. The
obvious selection bias and the relatively small number of
subjects in this observational part of the study hamper
the interpretation of the results. In the main publication
reporting trial results, no lung cancer risk differences
were found between former asbestos mine workers
randomized to beta-carotene or retinol [11]. However,
the risk of developing malignant mesothelioma was
significantly lower in the retinol group compared to that
using beta-carotene (0.24; 95% CI: 0.07-0.86).
The secondary prevention trials were aimed at the
reduction of sputum atypia (two studies, [12, 13]) and
metaplasia (two studies, [14, 15]). These studies included
smokers and evaluated the impact of alpha-tocopherol,
beta-carotene, retinol, retinyl palmitate and isotretinoin.
No significant reduction of the evaluated markers was
observed (Table I), and smoking cessation was the only
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Table I. Completed chemoprevention trials in lung cancer
[ref] Prevention Study Number Agents Endpoints Result (RR; p-value)
setting group of patients
[7] I Smokers 29.133 BC/Vit. E Lung cancer incidence Harmful (1.18; 0.01)
[8] I Smokers, asbestos 18.314 BC+RA Lung cancer incidence Harmful (1.28; 0.02)
[9] I US physicians 22.071 BC Lung cancer incidence NS
[10] I Asbestos 2.199 BC/Retinol Lung cancer incidence NS
Mesothelioma incidence NS
[12] II Sputum atypia 150 Etretinate Sputum atypia NS
[13] II Sputum atypia 755 BC+RA Sputum atypia NS
[14] II Metaplasia 152 Isotretinoin Metaplasia index NS
[15] II Metaplasia 139 Fenretinide Metaplasia index NS
[19] III NSCLC 1486 Isotretinoin Rate of second primary tumors NS
[20] III NSCLC+HNC 2.592 N-acetylcysteine/ Rate of second primary tumors NS
Retinyl palmitate
[18] III NSCLC 307 Retinyl palmitate Rate of second primary tumors Positive (?; 0.045)
Abbreviations:
I – primary prevention, II – secondary prevention, III – tertiary prevention;
RR – relative risk, NS – not significant, BC – beta carotene, Vit. E – vitamin E, RA – retinoid acid;
NSCLC – non-small cell lung cancer, HNC – head and neck cancer
factor related to decreased metaplasia index and cell
proliferation [15].
Three phase III studies of tertiary chemoprevention
have been conducted in lung cancer, with high
expectations after positive results of short-term retinoid
assessment in head and neck cancer [16, 17].
The smallest of the three studies, reported by
Pastorino et al. [18], showed a borderline (p=0.045)
increase of time to SPT or recurrence in a group of 307
stage I NSCLC patients randomly assigned to 12 month
administration of retinol palmitate or placebo. This effect
was not translated into survival benefit.
In the phase III Lung Intergroup Trial, low-dose
isotretinoin was compared to placebo in a cohort of 1166
NSCLC pathologic stage I patients, randomized six weeks
to three years after surgery [19]. No reduction in the rate
of SPTs was observed, and neither was there a reduction
in recurrence or morbidity rate in the study group. 
In the Euroscan, EORTC open-label study, retinyl
palmitate and/or N-acetylcysteine was assessed with a 2 x
2 factorial design in 2592 lung cancer and early stage
head and neck patients who underwent curative therapy
[20]. The study was designed in both tumor types, due to
similar etiological and biological factors. This study failed
to show a clinical benefit of either agent on the incidence
of SPTs, event-free or overall survival. Importantly, in
the two above-mentioned studies, smoking cessation was
associated with better survival of the trial participants.
Reduction in SPTs after definite surgery for stage I
NSCLC is sought in a currently ongoing US intergroup
clinical study with planned accrual of 1960 patients,
evaluating the role of selenium supplementation. The
rationale for this study came from a number of epidemio-
logical studies suggesting an association between low
selenium concentration and the risk of cancer [21, 22].
The recently updated Nutritional Prevention of Cancer
Trial indicated that selenium supplementation in non-
melanoma skin cancer patients results in a non-significant
reduction of lung cancer incidence [23]. In the subgroup
analysis, this finding was significant in patients with lowest
pre-study selenium plasma levels, however the number
of events in the study did not allow for any firm con-
clusions. The precise mechanism of the chemopreven-
tative action of selenium remains unknown, although
several molecular targets for this effect have been
postulated [24]. Completed lung cancer chemoprevention
studies are summarized in Table I.
Biology of lung cancer premalignant lesions and
rationale for selection of surrogate markers
The chemoprevention studies in NSCLC involved more
than 70,000 individuals and lasted more than a decade.
The overwhelming logistical and economic burden of
these trials and their neutral or even harmful results
obviate the need for redefinition of the endpoints in the
design of future studies. It is speculated that a surrogate
endpoint may be a laboratory examination or a physical
sign which is a prerequisite of a meaningful endpoint,
such as lung cancer incidence or mortality [25, 26].
Surrogate endpoints may greatly improve the efficiency
and reduce the costs of clinical trials, mainly through
decreasing required sample size and shortening study
duration. However, the appropriate validation of surro-
gate markers and their predictive value for the true
clinical endpoints of the intervention remain to be
confirmed.
Recently, much attention was given to identifying
and validating molecular events preceding the develop-
ment of lung cancer as potential surrogate markers in
chemoprevention studies. It is not the intention of this
review to cover the molecular biology of premalignant
lesions (recent excellent reviews include: Winterhalder,
2004 [5] Franklin, 2000 [27], Wistuba, 1999 [28], Niklinski,
2002 [29]) but rather to point out these abnormalities,
which are of potential relevance in the design and conduct
of chemoprevention trials in lung cancer.
P r e n e o p l a s t i c  b r o n c h i a l  l e s i o n s  d e t e c t e d
o n  t h e  l e v e l  o f  t i s s u e  a n d  c e l l  m o r p h o l o g y
Several preinvasive changes, divided into squamous and
non-squamous, have been described and correlated to
the development of lung cancer [27]. Squamous prema-
lignant lesions include metaplasia, dysplasia and
carcinoma in situ; the latter two are included in the
current WHO classification of lung neoplasms [30]. On
the cellular level, these changes may be reflected by
atypia, often detected by sputum cytology. As some
studies indicate that metaplasia is often reversible while
dysplasia is not [28], the latter seems to be a more
appropriate indicator for lung cancer risk assessment and
monitoring of an intervention. To quantify metaplasia in
a more consistent manner, a metaplasia index was
developed [31]. This index was also used in the two
previously mentioned lung cancer secondary prevention
trials [14, 15]. The proportion of metaplastic and dys-
plastic changes in bronchial epithelium seems to depend
on the studied population and risk definition. Results of
a study performed at the M. D. Anderson Cancer Center
demonstrated that among high-risk participants (history
of over 20 pack-years who quit smoking for one year),
metaplasia was most prevalent [32]. In contrast to this
finding, more than half of the patients in the Colorado
study on high-risk patients (smoking history of over 30
pack-years, chronic obstructive pulmonary disease and
sputum atypia) had moderate or high-grade dysplasia or
carcinoma in situ [33]. Sputum atypia as a marker for
lung cancer risk assessment is currently a subject of
investigation in this study. Preliminary results demon-
strated a relative risk of 2.4 for developing lung cancer in
patients with moderate or severe atypia in sputum
compared to their counterparts without sputum atypia. By
adding information on the DNA hypermethylation status
of eight genes in the sputum, the relative risk of lung
cancer development increased to 7.9 [34].
Pathologic criteria of premalignant lesions may not
adequately reflect the risk for all lung cancer types.
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Currently, no morphological abnormality preceding the
development of small-cell lung cancer (SCLC) has been
identified. Diffuse idiopathic neuroendocrine cell hyper-
plasia has been linked to the development of carcinoid
tumors, although there are no strong data to support this
relation. Atypical adenomatous hyperplasia (AAH) has
been described as peripheral epithelial cell proliferation
with minimal cytologic atypia and stromal response [27].
This lesion is regarded as a preinvasive counterpart of
adenocarcinoma, but there have been no prospective
studies to clearly establish this link and quantify the risk.
A practical difficulty is the frequent occurrence of these
lesions in the small bronchioles, not accessible by
bronchoscopy.
C y t o g e n e t i c  a n d  m o l e c u l a r  b i o m a r k e r s
A number of molecular abnormalities on DNA, RNA or
protein level were described in premalignant bronchial
lesions as possible candidates for lung cancer risk
assessment. These findings were also correlated to
morphologic premalignant changes detected by fluo-
rescent bronchoscopy and microdissection techniques
[35, 36]. Candidate risk markers include Ki67, p53,
retinoid acid receptors, c-myc, erbB-1, erbB-2, cyclin D1,
cyclin E, bcl-2/bax, and gene hypermethylation markers
[37]. Multiple marker assessment and multivariate
analysis in the same population of individuals may yield
additional information on the risk of lung cancer
development [38]. Such an analysis is now also technically
feasible with microchip gene array or tissue array
technology.
Despite the above developments, for several reasons
these biomarkers cannot yet be considered as useful
candidates for surrogate markers in chemoprevention
studies. First, adequately low interobserver and inter-
laboratory variability must be established for any test to
be reproducible. Second, these markers have to be
validated in properly designed nested case-control studies
in untreated high risk cohorts, and require adequate
follow-up. An example of such a study currently under
way is the Colorado High Risk Cohort Study, initiated
in 1993. In this study, high-risk individuals with sputum
atypia are evaluated annually with sputum cytology and
tumor suppressor gene methylation analysis of the
sputum, and many individuals are followed up by fluo-
rescence bronchoscopy.
Molecular markers may also be used to quantify the
risk of lung cancer in relation to genetic susceptibility,
based on the polymorphism of carcinogen activation and
detoxification, as well as DNA repair enzymes [39, 40]. In
a recent case-control study including 136 individuals, low
activity of DNA oxidative damage repair enzyme OGG
(8-oxoguanine DNA N-glycosylase) was linked with
significantly higher odds for lung cancer development
[41]. Interestingly, the estimated risk associated with low
OGG activity was very high and independent of the risk
caused by smoking. This study, as well as others focusing
on cytochrome P450 and glutathione S-transferase
isoenzyme polymorphisms, may better define the high-
risk population and facilitate the proper evaluation of
chemoprevention measures.
N o v e l  a g e n t s  i n  c h e m o p r e v e n t i o n  t r i a l s
The above-mentioned molecular events improve our
understanding of lung cancer development, but also serve
as molecular targets for an early intervention. There are
a number of new agents considered as possible candidates
for chemoprevention and of those several are already
tested within clinical trials.
Eicosanoid pathway plays an important role in the
development of invasive malignancy from epithelial
premalignant lesions in many cancer types, including
NSCLC. Cyclooxygenase-2 (COX-2) is an inducible
enzyme responsible for the formation of prostaglandins
and tromboxanes from arachidonic acid. The high activity
of this enzyme in tumors is also linked with their
aggressiveness through upregulation of angiogenesis,
upregulation of matrix metalloproteinases (invasiveness)
and inhibition of apoptosis [42]. In a case-control
epidemiological study, the two-year use of non-selective
anti-inflammatory drugs or aspirin was associated with
an almost 70% reduction of lung cancer risk [43].
Selective COX-2 inhibitors (coxibs) are thus considered
potential chemoprevention agents and are currently
tested in a series of clinical trials. However, the recent
withdrawal of rofecoxib from the market due to high rate
of cardiovascular events clearly indicates the need for
careful toxicity evaluation of other selective COX-2
inhibitors. A potential candidate for chemoprevention
is lipooxygenase (LOX), an enzyme involved in the
conversion of arachidonic acid to leukotrienes [5]. LOX
inhibitors are already used in the treatment of asthma
and other inflammatory diseases. Another potentially
chemopreventive substance, already validated in a phase
I/II chemoprevention study, is prostacyclin PGI2 analogue
(iloprost), as its high levels were found to reduce tumor
formation in mice exposed to lung cancer carcinogens
[44].
The members of epidermal growth factor receptor
(EGFR) family mediate the signal transduction for EGF,
an important mediator of epithelial proliferation involved
in the pathogenesis of NSCLC. Moreover, recent data
indicate that EGFR tyrosine kinase mutational activation
is the leading molecular abnormality in a subpopulation of
NSCLC patients with specific features – non-smoking
females with adenocarcinoma [45, 46]. Novel agents
targeting EGF family include its tyrosine kinase inhibitors
(gefitinib, erlotinib and dual inhibitors – e.g. GW572016)
and monoclonal antibodies against their receptors
(cetuximab and trastuzumab targeting respectively EGFR
[erbB1] and erbB2. Due to the frequent heterodimeri-
zation of EGF family members, dual inhibition of erbB1
and erbB2 seems an attractive strategy of chemopreven-
tion and treatment of lung cancer.
Mutation of K-ras gene occurs in 20-40% of NSCLCs
and is an important molecular event in tumors with intact
73
EGFR pathway. Ras protein expression may be inhibited
through farnesyl transferase inhibitors, agents that also
block the expression of downstream signal mediators rho
and raf. Thus, also farnesyl transferase inhibitors may be
considered potential candidates for chemoprevention
trials.
Dithioloethiones are organosulfur compounds acting
mainly through the increased expression of phase II
detoxication enzymes (glutathione transferases) and
through free-radical scavenging. This class of agents
includes oltipraz and anethole dithiolethione. The latter
compound was evaluated in a phase II randomized
chemoprevention study in smokers with bronchial
dysplasia monitored by serial fluorescent bronchoscopy
[47]. Although no histological regression of dysplasia was
observed in this study, the dysplasia progression was
significantly delayed in the subjects receiving anethole
dithiolethione as compared with placebo.
S u r r o g a t e  m a r k e r s  –  s u r r o g a t e  e v i d e n c e ?
The need to include surrogate end-points is increasingly
important in cancer chemoprevention studies. There is,
however, considerable controversy about the usefulness
of these endpoints for clinical interventions, and this
controversy is supported by numerous studies showing
an apparent improvement in surrogate endpoint but no
benefit or even a harmful effect on clinical outcome, such
as incidence or mortality [48].
An example of a study that demonstrated the
paradoxically harmful clinical relevance of a potentially
useful surrogate marker is the Cardiac Arrhythmia
Suppression Trial (CAST [49, 50]). In this study, the
reduction of ventricular ectopic contractions (a surrogate)
by one of three class I antiarrhythmic agents (encainide,
flecainide and moricizine) was expected to result in
a decreased cardiovascular-related mortality (true
endpoint). At the time the trial was conducted, the drugs
had already been approved by the Food and Drug
Administration (FDA) and were used in daily practice.
Although the effect on a surrogate was achieved, the
number of deaths was significantly higher in the groups
randomly assigned to one of the three drugs, compared
with placebo. Clearly, a harmful effect measured by
overall survival was demonstrated for each drug, indi-
cating the unreliability of surrogate endpoints used earlier
in the drug approval process.
To be valid a surrogate endpoint must closely
correlate with the true clinical endpoint. More impor-
tantly, it must also predict the effect of intervention on
clinical outcome [25]. This frequently unrecognized
principle may not be met for many studies, and therefore
should be validated before a phase III clinical intervention
trial is set. In statistical terms, these requirements may be
indicated by two coefficients: the proportion of treatment
effect explained by a surrogate marker (PE) and the ratio
of the effects of treatment upon the final and surrogate
endpoint (RE, [51]). A number of methods have been
developed to calculate these parameters and their
confidence intervals in order to evaluate the validity of the
surrogate endpoint [51, 52]. These parameters may also
be used to compare the usefulness of different surrogates
in the studied population in terms of their adherence to
clinical outcomes.
The lack of the intervention effect on a surrogate
endpoint may also lead to the exclusion of a potentially
valuable treatment. In a study evaluating interferon-
gamma in immunocompromised children with chronic
granulomatous disease (CGD), this treatment was
expected to result in a more effective generation of
oxygen burst in mononuclear cells as a response to
infection. Surprisingly, the trial showed a significant
reduction of the rate of serious infections, without any
impact on a surrogate endpoint [48, 53].
Conclusions
Chemoprevention studies in lung cancer completed within
the last two decades indicate the need for the implemen-
tation of surrogate endpoints in the design of future trials
in order to perform these studies effectively and with fast
turnover. A large number of potentially active chemo-
prevention agents are available today. Given the large
number of new molecular targeted therapies potentially
reducing the incidence of lung cancer in high-risk
populations, there is a growing demand to properly
evaluate these endpoints before commencing the trial.
The necessity for the proper validation of surrogate
endpoints is indicated by numerous examples of mis-
leading preliminary findings.
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